Dr Beata Edling Appointed CEO of TruScreen Group

NZX/ASX Announcement
6 October 2022
Dr Beata Edling Appointed CEO of TruScreen Group

Truscreen Group Limited (NZX/ASX:TRU) (TruScreen or Company) is pleased to announce the
appointment of Dr. Beata Edling as Chief Executive Officer.

Dr. Edling joined TruScreen in October 2020 as Medical
Affairs and Market Access Lead and has developed an
intimate knowledge of the TruScreen cervical cancer
screening technology and business. She led the medical
affairs and market access of TruScreen into new markets in
Eastern Europe and the Balkan nations and inaugurated
TruScreen’s International Experts Group. Dr Edling has also
worked closely with TruScreen’s major distributors in
China and in Vietnam.
Chairman, Mr Tony Ho, said “as the world and our global markets normalise economic activities after
COVID, it is timely that TruScreen continues with commercialisation of our cervical cancer screening
technology. The appointment of Sydney based Dr. Edling will provide a sharper focus to growing our
business as border restrictions are removed from our markets. The past COVID years were devoted
to preparing the Company for post COVID commercial activities. We expect China to lift border
restrictions in the next few months.”
“I would like to thank Mrs Juliet Hull, our Non-Executive Director for stepping in to lead the Company
as Interim CEO during the past 20 months during the COVID period. Under Mrs Hull’s leadership,
much was achieved by TruScreen, including completion of the critical supplier contract with Zapco
International and transitioning of the global regulatory MDD to MDR platform. Mrs Hull will resume
her role as a Non-Executive Director of TruScreen.”
Dr. Edling holds a MD from the Medical University, Gdansk, Poland, and has completed part 1 of her
Fellowship with Royal College of Surgeons, Australia. Dr Edling completed her PhD at the University
of New South Wales, Australia, has a MBA from Sydney’s Australian Graduate School of
Management, and is a graduate member of the Australian Institute of Company Directors.
Dr. Edling is an experienced executive who previously led large and small Medical Affairs Teams and
commercialised numerous medical products with global pharmaceutical companies, Sanofi-Aventis,
Shire, Eli Lily and Amgen for Australia and New Zealand. Dr Edling was previously a Non-Executive
Director of ASX listed Noxopharm Limited. Dr. Edling is multi-lingual and speaks several European
languages.

For more information, visit www.truscreen.com or contact:

Tony Ho
Chairman
tonyho@truscreen.com

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/